Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Meiji Grants Carbapenem Rights to Spero Outside Japan, Asia
October 13, 2017
- Teijin Earns Japan Rights to Novel Botulinum Toxin
October 13, 2017
- Ono Grabs Rights to 2 XPO1 Inhibitors in Japan, Asia
October 13, 2017
- Daiichi Sankyo Initiates AMED-Funded Joint Research on Genetic Vaccine Platform with NIBIOHN
October 13, 2017
- LEO Pharma to Offer Cell Assays in Japan to Evaluate External Compounds under Unique Open Innovation Model
October 13, 2017
- FGF23 Antibody Burosumab Earns FDA Priority Status: Kyowa Kirin/Ultragenyx
October 12, 2017
- FDA Fast-Tracks Astellas’s AML Med Gilteritinib
October 12, 2017
- 3 Japan Drug Majors Launch Open Innovation Program for Drug Repositioning
October 12, 2017
- Harada Picked as Next Pfizer Japan President
October 12, 2017
- Bayer to Set Up Collaboration Research Center in Kobe in Early 2018 to Support Startups
October 12, 2017
- NanoCarrier, JCR to Collaborate on Brain Drug Delivery
October 11, 2017
- Hisamitsu Sees Lower Ethical Drug Sales in March-August
October 11, 2017
- Takeda Promoting Digital Innovations through IT Industry Approaches: Digital Acceleration Head
October 11, 2017
- Zytiga Gets Priority Review Status for Earlier Use in Prostate Cancer
October 11, 2017
- Torii to Skip November Listing of Tablet-Form Pollen Allergy Therapy
October 10, 2017
- Kyowa Kirin Pulls Plug on Tivantinib, Follows Daiichi Sankyo
October 10, 2017
- Nippon Kayaku Clinches Supreme Court Victory in Elplat Patent Suit
October 6, 2017
- AZ to Transfer Migraine Med Zomig to Sawai Mid-Next Year
October 6, 2017
- Daiichi Sankyo, Osaka Univ. Spin-Off to Jointly Develop iPS Cell-Derived Cardiomyocyte Sheet, Aiming at Commercialization within 5 Years
October 6, 2017
- Sanofi Files Spiramycin for Congenital Toxoplasmosis
October 6, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…